Premium
Inhibitory effect of azelastine, a potent antiallergic agent, on release of tumor necrosis factor‐α from activated human peripheral blood mononuclear cells and U937 cells
Author(s) -
Hamamoto Yoshiaki,
Nagai Kou,
Muto Masahiko,
Asagami Chidori
Publication year - 1993
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/j.1600-0625.1993.tb00038.x
Subject(s) - azelastine , tumor necrosis factor alpha , peripheral blood mononuclear cell , pharmacology , cytokine , u937 cell , histamine , immunology , chemistry , medicine , in vitro , biochemistry
It is generally accepted that tumor necrosis factor‐α (TNF‐α) is a multifunctional cytokine which is involved in the regulation of inflammation as well as immunity. In the present study, we investigated whether azelastine, a potent antiallergic agent, affects release of TNF‐α from peripheral blood mononuclear cells (PBMC) and U937 cell line in vitro . When human PBMC and U937 cells were stimulated by phytohemagglulinin (PHA) and 12‐0‐letradecanoyl‐phorbol‐13‐acetate (TPA). respectively, the cells released significant amounts of TNF‐α as determined by TNF‐α‐specific enzyme immunoassay. TNF‐α levels in the culture supernatant of PHA‐stimulated human PBMC and TPA‐activated U937 cells decreased in a dose‐dependent manner when these cells were cultured in the presence of azelastine. This inhibitory effect of azelastine was obtained at concentrations where the drug produced no toxicity. Moreover, azelastine also inhibited release of TNF‐α from U937 cells which were already activated by TPA. These results suggest that the inhibitory effect of azelastine on TNF‐α release plays an important role in its antiallergic action in addition to inhibition and/or antagonism of histamine and leukolriens, which has been previously reported.